Eli Lilly, BioAge chase NLRP3 inhibitors with ‘pipeline in a pill’ potential
Eli Lilly, BioAge chase NLRP3 inhibitors with ‘pipeline in a pill’ potential
Body unavailable. Use the original source.
Eli Lilly, BioAge chase NLRP3 inhibitors with ‘pipeline in a pill’ potential
A compact weekly email covering company moves, product signals, regulatory updates, and notable funding.